Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.

@article{Jacobstein2005PremedicationAI,
  title={Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.},
  author={Douglas A Jacobstein and Jonathan E. Markowitz and Barbara S. Kirschner and George D. Ferry and Stanley Allen Cohen and Benjamin D. Gold and Harland S. Winter and Melvin B. Heyman and Robert N Baldassano},
  journal={Inflammatory bowel diseases},
  year={2005},
  volume={11 5},
  pages={
          442-6
        }
}
BACKGROUND Infusion reactions (IRs) are the most common adverse events associated with the use of infliximab for inflammatory bowel disease (IBD). Antipyretics, antihistamines, and corticosteroids have been used to prevent the development of IRs, but their efficacy is not known. We studied the proportion of pediatric patients receiving infliximab for IBD that developed IRs and the potential effects of premedication on IR. METHODS Uniformly collected data from a cohort of pediatric patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…